Alfresa Holdings Corporation

Medium-term Management Plan

16-18 Mid-term Management Plan Break Through to Tomorrow

To further realize our principles, the Alfresa Group has formulated "16-18 Mid-term Management Plan Break Through to Tomorrow" with "Strengthen business foundation with one Alfresa initiatives," "Expand the health and medical-related fields," and "Reform business model ahead of changes in the business environment" as Group management policies called "Challenge 3."

16-18 Mid-term Management Plan

Group Management Policies

"Challenge 3"

  1. Strengthen Business Foundation with One Alfresa Initiatives
  2. Expand the Health and Medical-related Fields
  3. Reform Business Model Ahead of Changes in the Business Environment

Strengthen Business Foundation with One Alfresa Initiatives

We will work to spread the Alfresa Group brand through comprehensive approaches to medical institutions, dispensing pharmacies, manufacturers and others by bringing together the Group's strengths in each business segment and generating synergy.

Expand the Health and Medical-related Fields

We will invest management resources mainly in the health and medical-related fields to strengthen the Alfresa Group's distinctive business model centered on the ethical pharmaceuticals supply chain.

Reform Business Model Ahead of Changes in the Business Environment

We will promote reforms in each business segment ahead of changes in the business environment, and advance efforts toward strengthening profit foundations and expanding business. Additionally, we will leverage the know-how acquired with the strong business model in Japan to advance business expansion overseas, centered on Asia.

Ethical Pharmaceuticals Wholesaling Business
  • Marketing reform & distribution reform
  • Pursue optimization for the Alfresa Group
  • Advance "distribution reforms"
Self-medication Products Wholesaling Business
  • Further reinforce business foundations
  • Strengthen value-added marketing activities
Manufacturing Business
  • Advance consigned manufacturing and the active pharmaceutical ingredients business
  • Expand product lineup and reinforce sales capabilities
Medical-related Business
  • Address business model transformation
    –Switch from location-oriented to function-focused–

Group Management Targets

Net Sales 2.7 trillion yen
Operating Income Margin 1.5% +
Net Profit Margin* 1.2% +
  • Net profit margin attributable to owners of parent company
Investment(cumulative total in 16-18 plan) About 100 billion yen level
ROE 8% level
Shareholder Return Policy DOE* 2.0% +
  • DOE : Dividend on Equity